Choi April, Carpenter Philip M, Chopra Shefali, Lara Kristi M, Tseng William W, Patel Dakshesh B, Hu James
Department of Medicine, USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
Department of Medicine, LAC + USC Medical Center, Los Angeles, CA, USA.
Rare Tumors. 2020 Dec 11;12:2036361320977021. doi: 10.1177/2036361320977021. eCollection 2020.
Spindle cell carcinoma (SpC), also known as metaplastic carcinoma-spindle cell type, is a subtype of metaplastic carcinoma. Metaplastic carcinomas of the breast are rare but are thought to be more aggressive than invasive ductal carcinomas. Due to their rarity, there are few randomized trials that can inform any standardized approaches to treatment. Treatment is instead extrapolated from other types of breast cancer or metaplastic carcinomas of different locations. Here we present the first known case report of a patient with spindle cell carcinoma of the breast successfully treated with a standard sarcoma neoadjuvant regimen of doxorubicin, ifosfamide, and mesna (AIM) that resulted in >99% necrosis of the tumor and negative margins at the time of resection.
梭形细胞癌(SpC),也称为化生癌-梭形细胞型,是化生癌的一种亚型。乳腺化生癌很少见,但被认为比浸润性导管癌更具侵袭性。由于其罕见性,很少有随机试验能够为任何标准化治疗方法提供依据。相反,治疗方法是从其他类型的乳腺癌或不同部位的化生癌推断而来。在此,我们报告首例已知的乳腺梭形细胞癌患者,该患者成功接受了阿霉素、异环磷酰胺和美司钠(AIM)的标准肉瘤新辅助治疗方案,治疗后肿瘤坏死率>99%,切除时切缘阴性。